trending Market Intelligence /marketintelligence/en/news-insights/trending/-j01Pz-EKEkK_0TB6jah4g2 content esgSubNav
In This List

AbCellera, Pfizer partner to conduct antibody research

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


AbCellera, Pfizer partner to conduct antibody research

AbCellera Biologics Inc. and Pfizer Inc. entered a collaboration agreement for the discovery of new therapeutic antibodies.

AbCellera will use its proprietary monoclonal antibody screening platform to find function-modulating antibodies against undisclosed membrane protein targets.

Under the terms of the agreement, AbCellera will receive an upfront payment and research support and will be eligible to receive up to about $90 million in contingent milestone payments, as well as tiered mid-to-low single digit royalty payments based on Pfizer's development and commercialization of antibodies that may be generated under the collaboration.

Further terms of the agreement are not disclosed.